PathogenDx, Zef Scientific partner to offer microbial testing platform
Category: #health  By Paroma Bhattacharya  Date: 2019-07-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

PathogenDx, Zef Scientific partner to offer microbial testing platform

The propriety technology offered by PathogenDx will set a new standard in Canada for testing bacteria

PathogenDx, Inc., a technology company that provides testing solutions to food, agriculture and botanical testing markets, recently announced it has entered into a strategic partnership with Zef Scientific for sales and distribution of microbial testing in Canada.

Under the agreement, both companies aim to grow their accounts nationally, while the partnership has already wrapped up its first account with a testing lab in Canada.

Reportedly, Zef Scientific works with a number of major equipment manufacturers like Shimadzu and take pride in being able to provide laboratories with multi-vendor solutions. The company’s scope ranges from pharmaceutical laboratories to modern cannabis facilities for testing.

Kevork Kalaydjian, Sales Director at Zef Scientific said that the company’s new partnership with PathogenDx will expand their portfolio to include fungal and bacterial testing through PathogenDx’s offered technology, that is unique and DNA-based.

ZefSci is looking forward to offering new line of instrumentation to the Cannabis market in Canada. The proprietary technology offered by PathogenDx will help set a new standard for testing bacteria in the country, a solution that would make sense, Kalaydjian added.

Milan Patel, Co-Founder and CEO of PathogenDx said in an announcement that the partnership and agreement between PathogenDx and Zef Scientific will offer Canadian Cannabis market new access to ultra-fast microbial testing turnaround times. Owing to major regulatory mandates in order to protect recreational consumer safety and patients, the Canadian market has faced certain supply challenges.

The partnership will offer Canadian retailers, regulators, distributors and growers a chance to shorten approval times and testing with greater precision, while also securing safer and better products to market faster for consumers and patients in Canada, Patel mentioned.

Seemingly, molecular technologies are increasingly being adopted by Cannabis testing labs in order to meet the testing mandates for pathogen and avoid relying on culture based methods. Cannabis was legalized for recreational and medicinal use the previous year.

Source Credit- https://www.biospace.com/article/releases/pathogendx-and-zef-scientific-announce-a-strategic-sales-and-service-distribution-partnership-for-microbial-testing-in-canada/



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Aino Health inks deal with 55BirchStreet to expand in German markets
Aino Health inks deal with 55BirchStreet to expand in German markets
By Paroma Bhattacharya

Reports confirm that Sweden’s Aino Health and 55BirchStreet, a Germany-based digital consulting firm, have recently signed a new partnership agreement. 55BitchStreet will sell implementation services and licenses...

Visa acquires Payworks for an integrated payment acceptance solution
Visa acquires Payworks for an integrated payment acceptance solution
By Paroma Bhattacharya

Visa, the financial services company recently announced acquisition of Payworks, the Munich-based makers of payment gateway software for the POS (point of sale). The company plans to integrate cloud-based solution of P...

MacroGenics, I-Mab team up to develop & market enoblituzumab in China
MacroGenics, I-Mab team up to develop & market enoblituzumab in China
By Paroma Bhattacharya

MacroGenics, Inc. and I-Mab Biopharma, a U.S. and China based clinical-stage biopharmaceutical company that is committed to discover and develop biologics in autoimmune and immune-oncology diseases, have recently announc...